Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zagociguat - Cyclerion Therapeutics

Next Previous
Drug Profile

Zagociguat - Cyclerion Therapeutics

Alternative Names: CY-6463; IW-6463

Latest Information Update: 13 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Developer Cyclerion Therapeutics; Tisento Therapeutics
  • Class Antidementias; Antipsychotics; Nootropics; Small molecules
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mitochondrial disorders
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; MELAS syndrome; Mitochondrial disorders
  • No development reported Dementia; Schizophrenia

Most Recent Events

  • 06 May 2025 Tisento Therapeutics plans a phase II PRIZM trial for MELAS syndrome (PO, Tablet) in August 2025 (NCT06961344)
  • 28 Feb 2025 No recent reports of development identified for phase-I development in Schizophrenia(Treatment-experienced) in USA (PO, Tablet)
  • 10 Sep 2024 Phase-II clinical trials in MELAS syndrome in Germany, Australia, USA (PO) (NCT06402123)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top